{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:26:33Z","timestamp":1787955993160,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100003181","name":"National Niemann-Pick Disease Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003181","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Major challenges to health care access include low health insurance literacy, prohibitive costs, and insurance barriers. Niemann\u2013Pick disease (NPD), comprising acid sphingomyelinase deficiency (ASMD) and Niemann\u2013Pick type C (NPC), is a group of rare, autosomal recessive, highly heterogeneous, neurovisceral, life-threatening, relentlessly progressive lysosomal disorders. Patients experience debilitating systemic and neurological symptoms and substantial emotional and financial stress. Currently, these multifaceted disorders are managed symptomatically as there are no approved therapies. Given the considerable disease burden of NPD, timely access to quality health care is paramount for improving outcomes in these life-threatening disorders. Understanding health insurance literacy and access challenges among patients with NPD and their caregivers is a first step to overcoming treatment barriers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients from the Niemann\u2013Pick community participated in a health insurance literacy survey and follow-up telephone interviews on perceived access challenges. Of the 79 respondents who completed the survey, 67 participated in interviews. All respondents had stable health insurance coverage. However, 61% of respondents were unaware of Medicaid waivers and did not avail of them. Overall, 50% of respondents with childhood onset NPC selected Medicaid\/Medicare and private insurance; 35% utilized Medicaid waivers. Most respondents with ASMD had private insurance only. Although the Niemann\u2013Pick community demonstrated greater health insurance literacy than the general population, knowledge gaps exist in calculating insurance coverage, out-of-pocket maximums, and defining a formulary. The most frequently cited access burden was the process of obtaining medical care and services. Among respondents with ASMD, the greatest access burden was fear of unavailability of or access to medications and treatment. Access challenges adversely impacted patients\u2019 mental health and exacerbated physical symptoms. Delays and denials in obtaining essential medication, equipment, and services contributed to disease progression. Caregivers faced burnout and often questioned the utility of their advocacy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study identified knowledge gaps in health insurance literacy and challenges to access medication and health care services among individuals impacted by NPD. Patients and caregivers need the knowledge and skills to navigate a complicated health care system, understand their rights to medication and services and, ultimately, benefit from improved outcomes, especially in a post\u2013drug approval era.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02490-8","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T05:02:55Z","timestamp":1662094975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Health insurance literacy and health services access barriers in Niemann\u2013Pick disease: the patient and caregiver voice"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5688-9062","authenticated-orcid":false,"given":"George A.","family":"Diaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joslyn","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hopkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"2490_CR1","volume-title":"Measuring health insurance literacy: a call to action","author":"L Quincy","year":"2012","unstructured":"Quincy L. Measuring health insurance literacy: a call to action. Yonkers: Consumers Union; 2012."},{"issue":"2","key":"2490_CR2","doi-asserted-by":"publisher","first-page":"e2146792","DOI":"10.1001\/jamanetworkopen.2021.46792","volume":"5","author":"S Park","year":"2022","unstructured":"Park S, Langellier BA, Meyers DJ. Association of health insurance literacy with enrollment in traditional medicare, medicare advantage, and plan characteristics within medicare advantage. JAMA Netw Open. 2022;5(2):e2146792.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2490_CR3","first-page":"e272","volume":"5","author":"S Ghaddar","year":"2021","unstructured":"Ghaddar S. Medicare for all: a health insurance literacy perspective. Health Lit Res Pract. 2021;5(4):e272\u20135.","journal-title":"Health Lit Res Pract"},{"issue":"2","key":"2490_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11606-021-06819-0","volume":"37","author":"BF Yagi","year":"2022","unstructured":"Yagi BF, Luster JE, Scherer AM, Farron MR, Smith JE, Tipirneni R. Association of health insurance literacy with health care utilization: a systematic review. J Gen Intern Med. 2022;37(2):375\u201389.","journal-title":"J Gen Intern Med"},{"issue":"12","key":"2490_CR5","first-page":"1627","volume":"27","author":"L Holland","year":"2021","unstructured":"Holland L, Nelson ML, Westrich K, Campbell PJ, Pickering MK. The patient\u2019s medication access journey: a conceptual framework focused beyond adherence. J Manag Care Spec Pharm. 2021;27(12):1627\u201335.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"2490_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pop.2014.09.009","volume":"42","author":"M Scotten","year":"2015","unstructured":"Scotten M. Parental health literacy and its impact on patient care. Prim Care. 2015;42(1):1\u201316.","journal-title":"Prim Care"},{"issue":"Suppl 1","key":"2490_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/10810730.2015.1131776","volume":"21","author":"H Levy","year":"2016","unstructured":"Levy H, Janke A. Health literacy and access to care. J Health Commun. 2016;21(Suppl 1):43\u201350.","journal-title":"J Health Commun"},{"issue":"1","key":"2490_CR8","first-page":"e40","volume":"2","author":"RT Braun","year":"2018","unstructured":"Braun RT, Barnes AJ, Hanoch Y, Federman AD. Health literacy and plan choice: implications for medicare managed care. Health Lit Res Pract. 2018;2(1):e40\u201354.","journal-title":"Health Lit Res Pract"},{"issue":"1","key":"2490_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s13023-021-01943-w","volume":"16","author":"TLS Pasquini","year":"2021","unstructured":"Pasquini TLS, Goff SL, Whitehill JM. Navigating the U.S. health insurance landscape for children with rare diseases: a qualitative study of parents\u2019 experiences. Orphanet J Rare Dis. 2021;16(1):313.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2490_CR10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13023-018-0936-x","volume":"13","author":"P Kaufmann","year":"2018","unstructured":"Kaufmann P, Pariser AR, Austin C. From scientific discovery to treatments for rare diseases\u2014the view from the National Center for Advancing Translational Sciences\u2014Office of Rare Diseases Research. Orphanet J Rare Dis. 2018;13(1):196.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2490_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/s13023-021-02061-3","volume":"16","author":"A Tisdale","year":"2021","unstructured":"Tisdale A, Cutillo CM, Nathan R, Russo P, Laraway B, Haendel M, et al. The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems. Orphanet J Rare Dis. 2021;16(1):429.","journal-title":"Orphanet J Rare Dis"},{"key":"2490_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1172-5-16","volume":"5","author":"MT Vanier","year":"2010","unstructured":"Vanier MT. Niemann\u2013Pick disease type C. Orphanet J Rare Dis. 2010;5:16.","journal-title":"Orphanet J Rare Dis"},{"issue":"1\u20132","key":"2490_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ymgme.2016.12.008","volume":"120","author":"EH Schuchman","year":"2017","unstructured":"Schuchman EH, Desnick RJ. Types A and B Niemann\u2013Pick disease. Mol Genet Metab. 2017;120(1\u20132):27\u201333.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"2490_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ymgme.2018.11.014","volume":"126","author":"M Wasserstein","year":"2019","unstructured":"Wasserstein M, Dionisi-Vici C, Giugliani R, Hwu WL, Lidove O, Lukacs Z, et al. Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD). Mol Genet Metab. 2019;126(2):98\u2013105.","journal-title":"Mol Genet Metab"},{"issue":"23","key":"2490_CR15","doi-asserted-by":"publisher","first-page":"12870","DOI":"10.3390\/ijms222312870","volume":"22","author":"C Pinto","year":"2021","unstructured":"Pinto C, Sousa D, Ghilas V, Dardis A, Scarpa M, Macedo MF. Acid sphingomyelinase deficiency: a clinical and immunological perspective. Int J Mol Sci. 2021;22(23):12870.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2490_CR16","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/gim.2017.7","volume":"19","author":"MM McGovern","year":"2017","unstructured":"McGovern MM, Dionisi-Vici C, Giugliani R, Hwu P, Lidove O, Lukacs Z, et al. Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency. Genet Med. 2017;19(9):967\u201374.","journal-title":"Genet Med"},{"issue":"2","key":"2490_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1212\/01.wnl.0000194208.08904.0c","volume":"66","author":"MM McGovern","year":"2006","unstructured":"McGovern MM, Aron A, Brodie SE, Desnick RJ, Wasserstein MP. Natural history of Type A Niemann\u2013Pick disease: possible endpoints for therapeutic trials. Neurology. 2006;66(2):228\u201332.","journal-title":"Neurology"},{"issue":"3","key":"2490_CR18","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ymgme.2016.05.001","volume":"118","author":"D Cassiman","year":"2016","unstructured":"Cassiman D, Packman S, Bembi B, Turkia HB, Al-Sayed M, Schiff M, et al. Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (Niemann\u2013Pick disease type B and B variant): literature review and report of new cases. Mol Genet Metab. 2016;118(3):206\u201313.","journal-title":"Mol Genet Metab"},{"issue":"8","key":"2490_CR19","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/gim.2013.4","volume":"15","author":"MM McGovern","year":"2013","unstructured":"McGovern MM, Lippa N, Bagiella E, Schuchman EH, Desnick RJ, Wasserstein MP. Morbidity and mortality in type B Niemann\u2013Pick disease. Genet Med. 2013;15(8):618\u201323.","journal-title":"Genet Med"},{"key":"2490_CR20","doi-asserted-by":"publisher","first-page":"100879","DOI":"10.1016\/j.spen.2021.100879","volume":"37","author":"E Berry-Kravis","year":"2021","unstructured":"Berry-Kravis E. Niemann\u2013Pick disease, type C: diagnosis, management and disease-targeted therapies in development. Semin Pediatr Neurol. 2021;37:100879.","journal-title":"Semin Pediatr Neurol"},{"issue":"1","key":"2490_CR21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1186\/s13023-021-02105-8","volume":"16","author":"E Mengel","year":"2021","unstructured":"Mengel E, Patterson MC, Chladek M, Guldberg C, et al. Impacts and Burden of Niemann pick Type-C: a patient and caregiver perspective. Orphanet J Rare Dis. 2021;16(1):493.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2490_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13023-018-0785-7","volume":"13","author":"T Geberhiwot","year":"2018","unstructured":"Geberhiwot T, Moro A, Dardis A, Ramaswami U, Sirrs S, Marfa MP, et al. Consensus clinical management guidelines for Niemann-Pick disease type C. Orphanet J Rare Dis. 2018;13(1):50.","journal-title":"Orphanet J Rare Dis"},{"key":"2490_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/8904_2018_120","volume":"41","author":"GF Cox","year":"2018","unstructured":"Cox GF, Clarke LA, Giugliani R, McGovern MM. Burden of illness in acid sphingomyelinase deficiency: a retrospective chart review of 100 patients. JIMD Rep. 2018;41:119\u201329.","journal-title":"JIMD Rep"},{"issue":"1","key":"2490_CR24","doi-asserted-by":"publisher","first-page":"20972","DOI":"10.1038\/s41598-021-99921-6","volume":"11","author":"R Pokrzywinski","year":"2021","unstructured":"Pokrzywinski R, Hareendran A, Nalysnyk L, Cowie S, Crowe J, Hopkin J, et al. Impact and burden of acid sphingomyelinase deficiency from a patient and caregiver perspective. Sci Rep. 2021;11(1):20972.","journal-title":"Sci Rep"},{"issue":"1","key":"2490_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13023-017-0572-x","volume":"12","author":"MM McGovern","year":"2017","unstructured":"McGovern MM, Avetisyan R, Sanson BJ, Lidove O. Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD). Orphanet J Rare Dis. 2017;12(1):41.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2490_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3111\/13696990903245863","volume":"12","author":"J Imrie","year":"2009","unstructured":"Imrie J, Galani C, Gairy K, Lock K, Hunsche E. Cost of illness associated with Niemann\u2013Pick disease type C in the UK. J Med Econ. 2009;12(3):219\u201329.","journal-title":"J Med Econ"},{"key":"2490_CR27","unstructured":"Bajwa H, Azhar W. Niemann\u2013Pick Disease. StatPearls. Treasure Island (FL);2022."},{"key":"2490_CR28","unstructured":"Mayo Clinic. Niemann-Pick care at Mayo Clinic. https:\/\/www.mayoclinic.org\/diseases-conditions\/niemann-pick\/care-at-mayo-clinic\/mac-20355892. Accessed 13 July 2022."},{"key":"2490_CR29","unstructured":"Sanofi. Press Release: Xenpozyme\u00ae (olipudase alfa) approved by European Commission as first and only treatment for ASMD 2022. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2022\/2022-06-28-05-30-00-2469974. Accessed 13 July 2022."},{"key":"2490_CR30","unstructured":"Academy of Managed Care Pharmacy. Formulary Management 2019. https:\/\/www.amcp.org\/about\/managed-care-pharmacy-101\/concepts-managed-care-pharmacy\/formulary-management. Accessed 13 July 2022."},{"key":"2490_CR31","unstructured":"Emily Johnson. What is a Medicaid waiver program? Medical News Today, 2021. https:\/\/www.medicalnewstoday.com\/articles\/medicaid-waiver-program#waiver-rules. Accessed 13 July 2022."},{"key":"2490_CR32","unstructured":"Definitions of health insurance terms. https:\/\/www.bls.gov\/ncs\/ebs\/sp\/healthterms.pdf. Accessed 13 July 2022."},{"key":"2490_CR33","unstructured":"Miglustat: Drug Information 2022. https:\/\/www.medilib.ir\/uptodate\/show\/10244. Accessed 11 April 2022."},{"key":"2490_CR34","doi-asserted-by":"crossref","unstructured":"Politi MC, Kuzemchak MD, Liu J, Barker AR, Peters E, Ubel PA, et al. Show me my health plans: using a decision aid to improve decisions in the federal health insurance marketplace. MDM Policy Pract. 2016;1.","DOI":"10.1177\/2381468316679998"},{"key":"2490_CR35","unstructured":"Tips for finding financial aid: Genetic and Rare Diseases Information Center; updated May 28, 2020. https:\/\/rarediseases.info.nih.gov\/Guides\/pages\/149\/tips-for-finding-financial-aid. Accessed 11 Feb 2022."},{"key":"2490_CR36","unstructured":"Financial Support: Every Life Foundation for Rare Diseases. https:\/\/everylifefoundation.org\/financial-support\/. Accessed 11 Feb 2022."},{"issue":"Suppl 2","key":"2490_CR37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/10810730.2014.936568","volume":"19","author":"KA Paez","year":"2014","unstructured":"Paez KA, Mallery CJ, Noel H, Pugliese C, McSorley VE, Lucado JL, et al. Development of the Health Insurance Literacy Measure (HILM): conceptualizing and measuring consumer ability to choose and use private health insurance. J Health Commun. 2014;19(Suppl 2):225\u201339.","journal-title":"J Health Commun"},{"key":"2490_CR38","unstructured":"Norton M, Hamel L. Assessing Americans' familiarity with health insurance terms and concepts: Kaiser Family Foundation; 2014. www.kff.org\/health-reform\/poll-finding\/assessing-americans-familiarity-with-health-insurance-terms-and-concepts\/. Accessed 10 Jan 2022."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02490-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02490-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02490-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T05:10:52Z","timestamp":1662095452000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02490-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2490"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02490-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]},"assertion":[{"value":"2 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study procedures were in accordance with ethical standards of the 1964 Helsinki Declaration and its later amendments, relevant laws, and institutional guidelines and approved by the Western Institutional Review Board and Copernicus Group Institutional Review Board. Online written informed consent was obtained from all participants or their caregivers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Online written consent for publication of aggregated and individual anonymized data was obtained from all respondents.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GAD is an investigator on a clinical trial of olipudase alfa sponsored by Sanofi and served as a scientific consultant to Sanofi. JC and JH declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"332"}}